+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hemato Oncology Testing Market Size, Share & Trends Analysis Report By Product (Assay Kits & Reagents, Services), By Cancer Type (Leukemia, Lymphoma), By Technology, By End-use, By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 150 Pages
  • August 2023
  • Region: Global
  • Grand View Research
  • ID: 5876164
Description Jump to:
The global hemato oncology testing market size is expected to reach USD 8.0 billion by 2030, growing at a CAGR of 12.54% from 2023 to 2030. The rising prevalence of myeloma and lymphoma is expected to fuel market growth during the projected period. According to the American Cancer Society, there will be about 34,470 new instances of multiple myeloma diagnosed in the United States in 2022, including 15,370 women and 19,100 men. In 2022, there will be a total of 12,640 deaths, including 5,550 women and 7,090 males. Thus, a rise in the prevalence of these diseases is expected to increase the usage of hemato-oncology testing products.

The market is experiencing a notable trend of growth and innovation. With advancements in technology and an increased understanding of molecular mechanisms in cancer, there is a growing demand for specialized tests to diagnose and monitor hematological malignancies and solid tumors. The market is witnessing a shift toward personalized medicine, where precise and targeted therapies are tailored to individual patients based on their genetic profiles. This has led to the development of companion diagnostic tests and the integration of Next-Generation Sequencing (NGS) and other advanced molecular techniques in hemato oncology testing. The market is expected to continue expanding as precision medicine approaches and gains prominence and new technologies further enhance diagnostic capabilities.

Growing collaborations among major companies and research organizations, as well as an increase in the number of research activities conducted by academic and research institutes to create technologically superior hemato oncology tests, are expected to drive market growth. For instance, in March 2022, Sanofi collaborated with Blackstone Life Sciences to advance the treatment of multiple myeloma by investing USD 328.91 million. This will further accelerate the testing and treatment of multiple myeloma.

An increase in the number of product launches is another major factor driving market growth. For instance, in July 2021, Thermo Fisher Scientific extended its hematology-oncology NGS portfolio by adding a new collection of Ion Torrent Oncomine immune range assays. With this launch, the company aimed to help researchers in getting a better analysis of blood cancers.

Furthermore, the increasing involvement of the research community in developing precision medicine is further accelerating market growth. For instance, in September 2021, the University of Cincinnati Cancer Center launched a personalized medicine trial named Beat AML for patients with acute myeloid leukemia (AML). The UC has collaborated with several institutes for this study. Thus, the rising focus on personalized therapy has helped significantly increase awareness about blood cancers and their subtypes, facilitating market growth.

Hemato Oncology Testing Market Report Highlights

  • In terms of cancer type, lymphoma dominated the market in 2022 with the largest revenue share of 46.66% owing to an increase in the prevalence of Hodgkin and Non-Hodgkin Lymphoma
  • In terms of product, the services segment held the largest revenue share of 58.23% in 2022 owing to an increase in the incidence rate of cancer and increased awareness about various treatment options such as tailored medicines
  • Based on technology, the PCR segment dominated the market in 2022 with the largest revenue share of 31.08% and witnessed exponential growth owing to its ease of use, accuracy, affordability, and efficiency, as well as an increase in the number of product launches and approvals
  • In terms of end-use, the hospitals segment is anticipated to witness the fastest CAGR of 12.8% during the forecast period. It also held the largest revenue share of 75.07% in 2022 owing to the accessibility of hemato oncology diagnostic tests and the existence of healthcare experts to perform diagnostic tests and monitor the disease
  • North America is expected to witness the fastest CAGR of 13.6% during the forecast period owing to a rise in the prevalence of multiple myeloma, growing awareness, and the launch of technologically advanced products for the diagnosis of hemato oncology

Table of Contents

Chapter 1. Methodology And Scope
1.1. Market Segmentation And Scope
1.1.1. Segment Definitions
1.1.1.1. Product Segment
1.1.1.2. Technique Segment
1.1.1.3. Type Segment
1.1.1.4. Application Segment
1.1.1.5. Scale Of Operations Segment
1.2. Information Procurement
1.2.1. Market Formulation & Data Visualization
1.2.2. Data Validation & Publishing
1.3. Research Assumptions
1.4. Research Methodology
1.4.1. Purchased Database
1.4.2. Analyst's Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details Of Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.1.1. Approach 1: Commodity Flow Approach
1.8. List Of Secondary Sources
1.9. Global Market: CAGR Calculation
1.10. Objectives
1.10.1. Objective 1
1.10.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Cancer Type And Product Snapshot
2.3. Technology And End-Use Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Hemato Oncology Testing Market Variables And Trends
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Impact Analysis
3.2.1.1. Increasing Prevalence Of Lymphoma & Myeloma
3.2.1.2. Growing Demand For Personalized Therapy
3.2.1.3. Availability Of Advanced Molecular Techniques For Hemato-Oncology Diagnostics
3.2.1.4. Increasing Drug-Diagnostics Co-Development
3.2.2. Market Restraint Impact Analysis
3.2.2.1. Unfavorable Reimbursement Scenario.
3.3. Impact Of The Covid-19 Pandemic
3.4. Industry Analysis Tools
3.4.1. Porter’s Analysis
3.4.2. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
Chapter 4. Hemato Oncology Testing Market: Cancer Type Estimates & Trend Analysis
4.1. Cancer Type Movement Analysis & Market Share, 2022 & 2030
4.2. Hemato Oncology Testing Market Estimates & Forecast, By Cancer Type (USD Million)
4.3. Leukemia
4.3.1. Global Leukemia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.3.2. Acute Myeloid Leukemia (AML)
4.3.2.1. Global Acute Myeloid Leukemia (AML) Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.3.3. Acute Lymphocytic Leukemia (ALL)
4.3.3.1. Global Acute Lymphocytic Leukemia (ALL) Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.3.4. Chronic Lymphocytic Leukemia
4.3.4.1. Global Chronic Lymphocytic Leukemia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.3.5. Chronic Myeloid Leukemia
4.3.5.1. Global Chronic Myeloid Leukemia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4. Lymphoma
4.4.1. Global Lymphoma Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.2. Non-Hodgkin Lymphoma
4.4.2.1. Global Non-Hodgkin Lymphoma Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4.3. Hodgkin Lymphoma
4.4.3.1. Global Hodgkin Lymphoma Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.5. Myeloproliferative Neoplasms
4.5.1. Global Myeloproliferative Neoplasms Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.5.2. Polycythemia Vera (PV)
4.5.2.1. Global Polycythemia Vera (PV) Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.5.3. Essential Thrombocythemia (ET)
4.5.3.1. Global Essential Thrombocythemia (ET) Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.5.4. Myelofibrosis (MF)
4.5.4.1. Global Myelofibrosis (MF) Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.6. Others Cancers
4.6.1. Global Others Cancers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Hemato Oncology Testing Market: Product Estimates & Trend Analysis
5.1. Product Movement Analysis & Market Share, 2022 & 2030
5.2. Hemato Oncology Testing Market Estimates & Forecast, By Product (USD Million)
5.3. Assay Kits And Reagents
5.3.1. Global Assay Kits And Reagents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4. Services
5.4.1. Global Services Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Hemato Oncology Testing Market: Technology Estimates & Trend Analysis
6.1. Technology Movement Analysis & Market Share, 2022 & 2030
6.2. Hemato Oncology Testing Market Estimates & Forecasts, By Technology (USD Million)
6.3. PCR
6.3.1. Global PCR Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.2. Real-Time qPCR
6.3.2.1. Global Real-Time qPCR Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.3.3. Digital PCR
6.3.3.1. Global Digital PCR Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4. Ihc
6.4.1. Global IHC Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5. Ngs
6.5.1. Global NGS Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.6. Cytogenetics
6.6.1. Global Cytogenetics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.7. Other Technologies
6.7.1. Global Other Technologies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Hemato Oncology Testing Market: Application Estimates & Trend Analysis
7.1. Application Movement Analysis & Market Share, 2022 & 2030
7.2. Hemato Oncology Testing Market Estimates & Forecast, By Application (USD Million)
7.3. Hospitals
7.3.1. Global Hospitals Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4. Academic & Research Institutes
7.4.1. Global Academic & Research Institutes Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5. Others
7.5.1. Global Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Hemato Oncology Testing Market: Regional Estimates And Trend Analysis
8.1. Hemato Oncology Testing Market: Regional Outlook
8.2. North America
8.2.1. North America Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Competitive Scenario
8.2.2.3. Regulatory Framework
8.2.2.4. U.S. Hemato Oncology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Competitive Scenario
8.2.3.3. Regulatory Framework
8.2.3.4. Canada Hemato Oncology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3. Europe
8.3.1. Europe Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.2. Germany
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. Regulatory Framework
8.3.2.4. Germany Hemato Oncology Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3.3. UK
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Regulatory Framework
8.3.3.4. UK Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Competitive Scenario
8.3.4.3. Regulatory Framework
8.3.4.4. France Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Competitive Scenario
8.3.5.3. Regulatory Framework
8.3.5.4. Italy Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Competitive Scenario
8.3.6.3. Regulatory Framework
8.3.6.4. Spain Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.7. Russia
8.3.7.1. Key Country Dynamics
8.3.7.2. Competitive Scenario
8.3.7.3. Regulatory Framework
8.3.7.4. Russia Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.8. Denmark
8.3.8.1. Key Country Dynamics
8.3.8.2. Competitive Scenario
8.3.8.3. Regulatory Framework
8.3.8.4. Denmark Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.9. Sweden
8.3.9.1. Key Country Dynamics
8.3.9.2. Competitive Scenario
8.3.9.3. Regulatory Framework
8.3.9.4. Sweden Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.3.10. Norway
8.3.10.1. Key Country Dynamics
8.3.10.2. Competitive Scenario
8.3.10.3. Regulatory Framework
8.3.10.4. Norway Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. Japan Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. China Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Framework
8.4.4.4. India Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.5. South Korea
8.4.5.1. Key Country Dynamics
8.4.5.2. Competitive Scenario
8.4.5.3. Regulatory Framework
8.4.5.4. South Korea Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.6. Singapore
8.4.6.1. Key Country Dynamics
8.4.6.2. Competitive Scenario
8.4.6.3. Regulatory Framework
8.4.6.4. Singapore Asia Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.7. Australia
8.4.7.1. Key Country Dynamics
8.4.7.2. Competitive Scenario
8.4.7.3. Regulatory Framework
8.4.7.4. Australia Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.4.8. Thailand
8.4.8.1. Key Country Dynamics
8.4.8.2. Competitive Scenario
8.4.8.3. Regulatory Framework
8.4.8.4. Thailand Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Brazil Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.3. Mexico
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. Mexico Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.5.4. Argentina
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. Argentina Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6. MEA
8.6.1. MEA Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.2. South Africa
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. South Africa Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. Saudi Arabia Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.4. UAE
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Framework
8.6.4.4. UAE Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
8.6.5. Kuwait
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Regulatory Framework
8.6.5.4. Kuwait Hemato Oncology Testing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Hemato Oncology Testing Market: Competitive Landscape
9.1. Participant Categorization
9.1.1. Amoy Diagnostics Co. Ltd
9.1.1.1. Overview
9.1.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.1.3. Product Benchmarking
9.1.1.4. Strategic Initiatives
9.1.2. EntroGen
9.1.2.1. Overview
9.1.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.2.3. Product Benchmarking
9.1.2.4. Strategic Initiatives
9.1.3. Cepheid
9.1.3.1. Overview
9.1.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.3.3. Product Benchmarking
9.1.3.4. Strategic Initiatives
9.1.4. ASURAGEN, INC
9.1.4.1. Overview
9.1.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.4.3. Product Benchmarking
9.1.4.4. Strategic Initiatives
9.1.5. ArcherDX, Inc.
9.1.5.1. Overview
9.1.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.5.3. Product Benchmarking
9.1.5.4. Strategic Initiatives
9.1.6. Invivoscribe, Inc.
9.1.6.1. Overview
9.1.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.6.3. Product Benchmarking
9.1.6.4. Strategic Initiatives
9.1.7. Adaptive Biotechnologies
9.1.7.1. Overview
9.1.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.7.3. Product Benchmarking
9.1.7.4. Strategic Initiatives
9.1.8. Abbott
9.1.8.1. Overview
9.1.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.8.3. Product Benchmarking
9.1.8.4. Strategic Initiatives
9.1.9. ARUP Laboratories
9.1.9.1. Overview
9.1.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.9.3. Product Benchmarking
9.1.9.4. Strategic Initiatives
9.1.10. Illumina, Inc.
9.1.10.1. Overview
9.1.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.10.3. Product Benchmarking
9.1.10.4. Strategic Initiatives
9.1.11. Bio-Rad Laboratories, Inc.
9.1.11.1. Overview
9.1.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.11.3. Product Benchmarking
9.1.11.4. Strategic Initiatives
9.2. Participant’s Overview
9.3. Financial Performance
9.4. Product Benchmarking
9.5. Company Market Share Analysis, 2022
9.6. Strategy Mapping
9.6.1. Expansion
9.6.2. Acquisition
9.6.3. Product/Service Launch
9.6.4. Others
Chapter 10. Analyst View
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 List of key emerging companies/product disruptors/innovators
Table 4 North America hemato oncology testing market, by country, 2018 - 2030 (USD Million)
Table 5 North America hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 6 North America hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 7 North America hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 8 North America hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 9 U.S. hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 10 U.S. hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 11 U.S. hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 12 U.S. hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 13 Canada hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 14 Canada hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 15 Canada hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 16 Canada hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 17 Europe hemato oncology testing market, by country, 2018 - 2030 (USD Million)
Table 18 Europe hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 19 Europe hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 20 Europe hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 21 Europe hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 22 U.K. hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 23 U.K. hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 24 U.K. hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 25 U.K. hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 26 Germany hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 27 Germany hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 28 Germany hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 29 Germany hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 30 France hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 31 France hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 32 France hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 33 France hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 34 Italy hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 35 Italy hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 36 Italy hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 37 Italy hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 38 Spain hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 39 Spain hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 40 Spain hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 41 Spain hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 42 Sweden hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 43 Sweden hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 44 Sweden hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 45 Sweden hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 46 Russia hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 47 Russia hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 48 Russia hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 49 Russia hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 50 Denmark hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 51 Denmark hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 52 Denmark hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 53 Denmark hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 54 Norway hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 55 Norway hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 56 Norway hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 57 Norway hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 58 Asia Pacific hemato oncology testing market, by country, 2018 - 2030 (USD Million)
Table 59 Asia Pacific hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 60 Asia Pacific hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 61 Asia Pacific hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 62 Asia Pacific hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 63 Japan hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 64 Japan hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 65 Japan hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 66 Japan hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 67 China hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 68 China hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 69 China hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 70 China hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 71 India hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 72 India hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 73 India hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 74 India hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 75 South Korea hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 76 South Korea hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 77 South Korea hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 78 South Korea hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 79 Australia hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 80 Australia hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 81 Australia hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 82 Australia hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 83 Singapore hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 84 Singapore hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 85 Singapore hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 86 Singapore hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 87 Thailand hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 88 Thailand hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 89 Thailand hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 90 Thailand hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 91 Latin America hemato oncology testing market, by country, 2018 - 2030 (USD Million)
Table 92 Latin America hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 93 Latin America hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 94 Latin America hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 95 Latin America hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 96 Brazil hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 97 Brazil hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 98 Brazil hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 99 Brazil hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 100 Mexico hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 101 Mexico hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 102 Mexico hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 103 Mexico hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 104 Argentina hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 105 Argentina hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 106 Argentina hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 107 Argentina hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 108 MEA hemato oncology testing market, by country, 2018 - 2030 (USD Million)
Table 109 MEA hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 110 MEA hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 111 MEA hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 112 MEA hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 113 South Africa hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 114 South Africa hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 115 South Africa hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 116 South Africa hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 117 Saudi Arabia hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 118 Saudi Arabia hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 119 Saudi Arabia hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 120 Saudi Arabia hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 121 UAE hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 122 UAE hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 123 UAE hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 124 UAE hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 125 Kuwait hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 126 Kuwait hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 127 Kuwait hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 128 Kuwait hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Hemato Oncology Testing Market Segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market Outlook (2022)
Fig. 10 Segment Outlook
Fig. 11 Strategy framework
Fig. 12 Hemato Oncology Testing Market: Driver Impact
Fig. 13 Hemato Oncology Testing Market: Restraint Impact
Fig. 14 Porter’s Five Forces Analysis
Fig. 15 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 16 Global Hemato Oncology Testing Market, by Cancer Type, 2018 - 2030 (USD Million)
Fig. 17 Global Leukemia Market, 2018 - 2030 (USD Million)
Fig. 18 Global Acute Myeloid Leukemia Market, 2018 - 2030 (USD Million)
Fig. 19 Global Acute Lymphocytic Leukemia Market, 2018 - 2030 (USD Million)
Fig. 20 Global Chronic Lymphocytic Leukemia Market, 2018 - 2030 (USD Million)
Fig. 21 Global Chronic Myeloid Leukemia Market, 2018 - 2030 (USD Million)
Fig. 22 Global Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 23 Global Non-Hodgkin Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 24 Global Hodgkin Lymphoma Market, 2018 - 2030 (USD Million)
Fig. 25 Global Myeloproliferative Neoplasms Market, 2018 - 2030 (USD Million)
Fig. 26 Global Polycythemia vera Market, 2018 - 2030 (USD Million)
Fig. 27 Global Essential Thrombocythemia Market, 2018 - 2030 (USD Million)
Fig. 28 Global Myelofibrosis Market, 2018 - 2030 (USD Million)
Fig. 29 Global Others Cancers Market, 2018 - 2030 (USD Million)
Fig. 30 Global Hemato Oncology Testing Market, by Product, 2018 - 2030 (USD Million)
Fig. 31 Global Assay Kits and Reagents Market, 2018 - 2030 (USD Million)
Fig. 32 Global Services Market, 2018 - 2030 (USD Million)
Fig. 33 Global Hemato Oncology Testing Market, by Technology, 2018 - 2030 (USD Million)
Fig. 34 Global PCR Market, 2018 - 2030 (USD Million)
Fig. 35 Global Real-time qPCR Market, 2018 - 2030 (USD Million)
Fig. 36 Global Digital PCR Market, 2018 - 2030 (USD Million)
Fig. 37 Global IHC Market, 2018 - 2030 (USD Million)
Fig. 38 Global NGS Market, 2018 - 2030 (USD Million)
Fig. 39 Global Cytogenetics Market, 2018 - 2030 (USD Million)
Fig. 40 Global Others Technologies Market, 2018 - 2030 (USD Million)
Fig. 41 Global Hemato Oncology Testing Market, by End-Use, 2018 - 2030 (USD Million)
Fig. 42 Global Hospitals Market, 2018 - 2030 (USD Million)
Fig. 43 Global Academic & Research Institutes Market, 2018 - 2030 (USD Million)
Fig. 44 Global Others Market, 2018 - 2030 (USD Million)
Fig. 45 Hemato Oncology Testing Market Snapshot
Fig. 46 North America Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 47 North America SWOT Analysis, by factor (political & legal, economic and technological
Fig. 48 U.S. Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 49 Canada Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 50 Europe Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 51 Europe SWOT Analysis, by factor (political & legal, economic and technological)
Fig. 52 Germany Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 53 UK Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 54 France Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 55 Italy Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 56 Spain Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 57 Russia Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 58 Sweden Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 59 Denmark Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 60 Norway Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 61 Asia Pacific Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 62 Asia Pacific SWOT Analysis, by factor (political & legal, economic and technological)
Fig. 63 Japan Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 64 India Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 65 China Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 66 Thailand Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 67 Australia Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 68 Singapore Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 69 South Korea Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 70 Latin America Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 71 Latin America SWOT Analysis, by factor (political & legal, economic and technological)
Fig. 72 Brazil Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 73 Mexico Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 74 Argentina Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 75 Middle East and Africa Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 76 Middle East and Africa SWOT Analysis, by factor (political & legal, economic and technological)
Fig. 77 South Africa Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 78 Saudi Arabia Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 79 UAE Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 80 Kuwait Hemato Oncology Testing Market, 2018 - 2030 (USD Million)
Fig. 81 List of secondary sources

Companies Mentioned

  • Amoy Diagnostics Co. Ltd
  • EntroGen
  • Cepheid
  • ASURAGEN, INC
  • ArcherDX, Inc.
  • Invivoscribe, Inc.
  • Adaptive Biotechnologies
  • Abbott
  • ARUP Laboratories
  • Illumina, Inc.
  • Bio-Rad Laboratories, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages150
PublishedAugust 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 3.07 Billion
Forecasted Market Value ( USD ) by 2030 $ 8 Billion
Compound Annual Growth Rate12.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Hemato Oncology Testing Market by Products & Services, Cancer, Technology, End-User - Global Forecast 2025-2030 - Product Image

Hemato Oncology Testing Market by Products & Services, Cancer, Technology, End-User - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Hemato Oncology Testing Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Hemato Oncology Testing Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Hemato Oncology Testing Market Analysis & Forecast to 2024-2034 - Product Image

Hemato Oncology Testing Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From
Hemato Oncology Testing Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032) - Product Image

Hemato Oncology Testing Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)

  • Report
  • 151 Pages
  • Global
From
Hemato Oncology Testing Global Market Report 2024 - Product Image

Hemato Oncology Testing Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.